We can't do this alone, and we don't try to. Our programmes move forward through strategic, mutually beneficial partnerships with organisations that share our focus on patients with few options.
We in-license approved, clinical-stage or shelved compounds where we have identified a new use.
Shared programmes that combine a partner's asset or expertise with our repurposing and stratification work.
Joint work with academic groups on disease models, biomarkers and validation.
Working with charities and advocacy groups to shape priorities and study design.
We work with commercial partners to bring validated programmes to patients and maximise their reach.
Computational and experimental evidence to find a compound's next indication.
Biomarker-defined patient groups that sharpen every study.
A team committed to small populations that larger companies often overlook.
A UK company connected to the UK's research and rare-disease ecosystem.
Tell us about your asset, research or patient community and we'll get back to you.